APAC Expansion And Compounding Services Will Unlock Future Value

Key Takeaways

• Expansion into new regions and focus on personalized pharmaceuticals positions Fagron for future global growth as demand rises from aging populations and chronic conditions.
  
• Investment in automation, facility expansion, and quality strengthens operational efficiency and market leadership, paving the way for margin and earnings growth.
  
• Vulnerability to supply chain, integration, regulatory, and currency risks may challenge growth, profitability, and margins despite expansion and underlying demand momentum.

Catalysts

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide.

• The ongoing expansion into new regions-including the recent entry into the APAC market via the Bella Corp acquisition and direct presence in the UK and Serbia-positions Fagron to tap into growing global demand for personalized pharmaceuticals, supporting future revenue acceleration as demographic trends (aging populations, more chronic conditions) drive higher prescription volumes.
  
• Continued strong performance and investment in compounding services, coupled with rising drug shortages (notably GLP-1 therapies and broader supply chain disruptions), provide Fagron with an opportunity to further increase both revenues and net margins as healthcare systems lean more on specialized, flexible providers.
  
• Focused investments in automation and operational excellence-including expanding compounding facilities (Anazao Las Vegas, Tampa) and procurement savings-are expected to result in improved scalability, margin expansion, and cost efficiencies, raising future earnings potential.
  
• Regulatory emphasis on drug quality and safety is driving consolidation and higher barriers to entry in the compounding sector, strengthening Fagron's position as a compliant, vertically integrated multinational, and supporting long-term growth in both revenue and net margins.
  
• Increasing awareness of, and demand for, personalized healthcare and custom formulations-underscored by ongoing product and brand innovation, targeted prescriber education, and successful launches-expands Fagron's addressable market, underpinning steady long-term revenue and EBITDA expansion.

Fagron Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Fagron's revenue will grow by 11.7% annually over the next 3 years.
• Analysts assume that profit margins will increase from 9.6% today to 10.6% in 3 years time.
• Analysts expect earnings to reach €140.1 million (and earnings per share of €1.89) by about April 2029, up from €91.0 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €160.8 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 17.8x on those 2029 earnings, down from 18.1x today. This future PE is lower than the current PE for the GB Healthcare industry at 18.1x.
• Analysts expect the number of shares outstanding to grow by 0.21% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.27%, as per the Simply Wall St company report.

Risks

• The recent strong revenue growth in North America was significantly boosted by temporary GLP-1 drug shortages, which have now ended, creating a challenging year-on-year comparison for H2 2025 and potentially leading to slower growth and revenue volatility if no similar tailwinds arise.
  
• The company's dependence on cost advantages from Asian API/raw material suppliers, especially China and India, combined with evolving geopolitical risk (e.g., tariffs), exposes Fagron to potential input cost inflation and supply chain disruptions-pressuring gross margins and overall profitability.
  
• While Fagron is expanding into new markets like APAC and integrating multiple small acquisitions, these new businesses are currently less profitable than the core group; realization of synergies is uncertain, and prolonged sub-par margins or integration challenges could weigh on group-level EBITDA and net margins.
  
• Weakening emerging market currencies (notably the Brazilian real) are adversely impacting reported revenues and profits in Latin America, and continued FX volatility or macroeconomic shocks in core non-EU regions could undermine revenue stability and earnings quality despite strong constant-currency underlying growth.
  
• Industry-wide regulatory scrutiny (e.g., FDA actions on compounding and tighter global quality standards), increasing compliance costs, and the phasing out of certain compounded drugs (like GLP-1s for weight loss) could constrain Fagron's product offering, raise operating expenses, and dampen long-term revenue and margin expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of €28.25 for Fagron based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €1.3 billion, earnings will come to €140.1 million, and it would be trading on a PE ratio of 17.8x, assuming you use a discount rate of 6.3%.
• Given the current share price of €22.5, the analyst price target of €28.25 is 20.4% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.